SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000; 343: 905914.
  • 2
    Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000; 355: 10411047.
  • 3
    Venook AP. Update on hepatic intra-arterial chemotherapy. Oncology. 1997; 11: 947970.
  • 4
    Rougier P. Are there indications for intraarterial hepatic chemotherapy or isolated liver perfusion? The case of liver metastases from colorectal cancer. Recent Results Cancer Res. 1998; 147: 312.
  • 5
    Hohn DC, Stagg RJ, Friedman MA, et al. A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California oncology group trial. J Clin Oncol. 1989; 7: 16461654.
  • 6
    Kemeny N, Daly J, Reichman B, Geller N, Botet J, Oderman P. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. Ann Intern Med. 1987; 107: 459465.
  • 7
    Chang AE, Schneider PD, Sugarbaker PH, Simpson C, Culnane M, Steinberg SM. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg. 1987; 206: 685693.
  • 8
    Martin JK, O'Connel MJ, Wieand HS, et al. Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. Arch Surg. 1990; 125: 10221027.
  • 9
    Meta-Analysis Group in Cancer. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst. 1996; 88: 252258.
  • 10
    Harmantas A, Rothstein LE, Langer B. Regional versus systemic chemotherapy in the treatment of colorectal carcinoma metastatic to the liver. Is there a survival difference? Meta-analysis of the published literature. Cancer. 1996; 78: 16391645.
  • 11
    Lorenz M, Muller HH. Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J Clin Oncol. 2000; 18: 243254.
  • 12
    Fordy C, Glover C, Davies MM, Allen-Mersh TG. Hepatic arterial floxuridine as second-line treatment for systemic fluorouracil-resistant colorectal liver metastases. Br J Cancer. 1998; 78: 10581060.
  • 13
    Patt YZ, Hoque A, Lozano R, et al. Phase II trial of hepatic arterial infusion of fluorouracil and recombinant human interferon alfa-2b for liver metastases of colorectal cancer refractory to systemic fluorouracil and leucovorin. J Clin Oncol. 1997; 15: 14321438.
  • 14
    Alexander HR Jr., Weinreich DM. Treatment of unresectable cancers confined to liver using vascular isolation and perfusion. In: DeVitaVTJr., HellmanS, RosenbergSA, editors. Updates: principles and practice of oncology. 15th edition. Philadelphia: Lippincott Williams & Wilkins, 2001; 15: 116.
  • 15
    Alexander HR Jr. Isolation perfusion. In: DeVitaVTJr., HellmanS, RosenbergSA, editors. Cancer: principles and practice of oncology. 6th edition. Philadelphia: Lippincott Williams & Wilkins, 2001: 769776.
  • 16
    Alexander HR Jr., Bartlett DL, Libutti SK. Current status of isolated hepatic perfusion with or without tumor necrosis factor for the treatment of unresectable cancers confined to liver [review]. Oncologist. 2000; 5: 416424.
  • 17
    Oldhafer KJ, Lang H, Frerker M, et al. First experience and technical aspects of isolated liver perfusion for extensive liver metastasis. Surgery. 1998; 123: 622631.
  • 18
    Lindnér P, Fjälling M, Hafström L, et al. Isolated hepatic perfusion with extracorporeal oxygenation using hyperthermia, tumour necrosis factor alpha and melphalan. Eur J Surg Oncol. 1999; 25: 179185.
  • 19
    Alexander HR Jr., Bartlett DL, Libutti SK, Fraker DL, Moser T, Rosenberg SA. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol. 1998; 16: 14791489.
  • 20
    Bartlett DL, Libutti SK, Figg WD, Fraker DL, Alexander HR Jr. Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. Surgery. 2001; 129: 176187.
  • 21
    Libutti SK, Bartlett DL, Fraker DL, Alexander HR Jr. Technique and results of hyperthermic isolated hepatic perfusion with tumor necrosis factor and melphalan for the treatment of unresectable hepatic malignancies. J Am Coll Surg. 2000; 191: 519530.
  • 22
    Barker WC, Andrich MP, Alexander HR Jr., Fraker DL. Continuous intraoperative external monitoring of perfusate leak using I-131 human serum albumin during isolated perfusion of the liver and limbs. Eur J Nucl Med. 1995; 22: 12421248.
  • 23
    Lans TE, Bartlett DL, Libutti SK, et al. Role of tumor necrosis factor (TNF) on toxicity and cytokine production following isolated hepatic perfusion (IHP). Clin Cancer Res. 2001; 7: 784790.
  • 24
    Posner MC, Lienard D, Lejeune FJ, Rosenfelder D, Kirkwood J. Hyperthermic isolated limb perfusion with tumor necrosis factor alone for melanoma. Cancer J Sci Am. 1995; 1: 274280.
  • 25
    Alexander HR Jr. Bartlett DL, Libutti SK. National Cancer Institute experience with regional therapy for unresectable primary and metastatic cancer of the liver or peritoneal cavity. In: MarkmanM, editor. Current clinical oncology: regional chemotherapy: clinical research and practice. Totowa, NJ: Humana Press, 1999: 127150.
  • 26
    Walther MM, Jennings SB, Choyke PL, et al. Isolated perfusion of the kidney with tumor necrosis factor for localized renal-cell carcinoma. World J Urol. 1996; 14: S2S7.
  • 27
    Pogrebniak HW, Witt CJ, Terrill R, et al. Isolated lung perfusion with tumor necrosis factor: a swine model in preparation of human trials. Ann Thorac Surg. 1994; 57: 14771483.